Annick Keuth-Seithel
Darmstadt, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Microtracer-Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [14C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study.
Journal: Clinical pharmacology in drug development
Published: February 13, 2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib.
Journal: Clinical pharmacology and therapeutics
Published: December 18, 2024
Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.
Journal: Investigational new drugs
Published: February 28, 2022
Cladribine as a Potential Object of Nucleoside Transporter-Based Drug Interactions.
Journal: Clinical pharmacokinetics
Published: November 07, 2021
Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.
Journal: Investigational new drugs
Published: September 02, 2021
Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine.
Journal: Clinical pharmacokinetics
Published: July 28, 2021
Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants.
Journal: Clinical and translational science
Published: April 28, 2021
Absolute Bioavailability and Effect of Food on the Disposition of Safinamide Immediate Release Tablets in Healthy Adult Subjects.
Journal: Clinical pharmacology in drug development
Published: April 09, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026